December 1, 2020 -- The U.S. Food and Drug Administration (FDA) has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) for December 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine candidate from Moderna.
The committee will discuss the safety and effectiveness data provided by Moderna. The company submitted its EUA request for the messenger RNA (mRNA)-1273 vaccine candidate on November 30.
The agency plans to make background materials available to the public, including the agenda and committee roster. The committee will be composed of a chair, members with scientific and public health expertise, consumer and industry representatives, and potentially a patient representative. The committee will advise the agency, however the final decision on whether to authorize the vaccine for emergency use will be made by the FDA.
The FDA will livestream the VRBPAC meeting on its YouTube, Facebook, and Twitter channels, as well as from the FDA website.